Goldman Sachs analysts added Baxter (BAX) to the firm’s US Conviction List as part of its monthly update. The firm expects a turnaround in shares after a long period of underperformance catalyzed by the company’s “stable,” mid-single-digit, revenue growth, “significant” operating margin expansion and free cash flow growth. Goldman has a Buy rating on Baxter with a $42 price target
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: